iFSP1 is an inhibitor of apoptosis inducing factor mitochondria-associated 2/ferroptosis suppressor protein 1 (AIFM2/FSP1). It decreases cell viability in wild-type, but not glutathione peroxidase 4 (GPX4) knock-out, Pfa1 and HT1080 cells overexpressing AIFM2/FSP1, an effect that can be blocked by the ferroptosis inhibitor liproxstatin-1 (Item No. 17730). iFSP1 (3 μM) sensitizes a variety of human cancer cell lines to the ferroptosis inducer (1S,3R)-RSL3 (Item No. 19288).
iFSP1 is an inhibitor of apoptosis inducing factor mitochondria-associated 2/ferroptosis suppressor protein 1 (AIFM2/FSP1). It decreases cell viability in wild-type, but not glutathione peroxidase 4 (GPX4) knock-out, Pfa1 and HT1080 cells overexpressing AIFM2/FSP1, an effect that can be blocked by the ferroptosis inhibitor liproxstatin-1 (Item No. 17730). iFSP1 (3 μM) sensitizes a variety of human cancer cell lines to the ferroptosis inducer (1S,3R)-RSL3 (Item No. 19288).
Shipping & Handling
Shipped In
Wet ice in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.